Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 151-160 of 677 for Cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Phase I/​II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/​Without Prior 177Lu-PSMA RLT

    Rochester, MN

  2. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito

    Rochester, MN

  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    La Crosse, WI, Mankato, MN, Rochester, MN

  5. A Study of ONO-7475 in Patients With Acute Leukemias

    Jacksonville, FL

  6. Dietary and Topical Magnesium Replacement or Supplementation in Patients with Lymphoma

    Rochester, MN

  7. IL-2 plus FOLFOX and Nivolumab for Treatment of Peritoneal Metastases

    Rochester, MN

  8. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study to Evaluate Combination Therapy to Treat Newly-diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

    Rochester, MN

  10. Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer